IRIS
GRAGNANO, Felice
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.973
NA - Nord America 5.224
AS - Asia 4.823
SA - Sud America 729
Continente sconosciuto - Info sul continente non disponibili 531
AF - Africa 86
OC - Oceania 6
Totale 20.372
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 6.858
US - Stati Uniti d'America 5.096
SG - Singapore 1.731
CN - Cina 998
VN - Vietnam 776
IE - Irlanda 774
HK - Hong Kong 684
BR - Brasile 614
IT - Italia 418
GB - Regno Unito 230
DE - Germania 220
KR - Corea 208
IN - India 158
FR - Francia 103
CA - Canada 61
UA - Ucraina 60
GR - Grecia 54
AR - Argentina 53
BD - Bangladesh 51
AT - Austria 48
FI - Finlandia 44
JP - Giappone 42
MX - Messico 41
SE - Svezia 41
NL - Olanda 29
ID - Indonesia 28
TR - Turchia 25
IQ - Iraq 23
BE - Belgio 22
MA - Marocco 21
CO - Colombia 20
ZA - Sudafrica 16
EG - Egitto 15
ES - Italia 15
PK - Pakistan 15
KE - Kenya 13
PL - Polonia 13
SA - Arabia Saudita 11
UZ - Uzbekistan 11
EC - Ecuador 10
VE - Venezuela 9
CL - Cile 8
LT - Lituania 8
TN - Tunisia 7
CR - Costa Rica 6
HN - Honduras 6
IL - Israele 6
JO - Giordania 6
AU - Australia 5
JM - Giamaica 5
NP - Nepal 5
PY - Paraguay 5
TH - Thailandia 5
TW - Taiwan 5
AE - Emirati Arabi Uniti 4
CZ - Repubblica Ceca 4
KZ - Kazakistan 4
MY - Malesia 4
NO - Norvegia 4
PE - Perù 4
RS - Serbia 4
UY - Uruguay 4
CH - Svizzera 3
EU - Europa 3
IR - Iran 3
MD - Moldavia 3
PH - Filippine 3
RO - Romania 3
AL - Albania 2
AM - Armenia 2
AZ - Azerbaigian 2
BW - Botswana 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
KH - Cambogia 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
AN - Antille olandesi 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GH - Ghana 1
GT - Guatemala 1
GY - Guiana 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
Totale 19.827
Salva come PNG Salva come JPEG
Città #
Moscow 2.579
San Jose 991
Singapore 772
Dublin 760
Santa Clara 710
Hong Kong 669
Chandler 359
Ashburn 327
Ho Chi Minh City 261
Hefei 246
Seoul 200
Hanoi 181
Beijing 143
New York 138
Dallas 103
The Dalles 102
Jacksonville 101
Princeton 94
Roxbury 94
Bengaluru 90
Los Angeles 82
Naples 70
São Paulo 56
Da Nang 55
Nuremberg 53
Cambridge 49
Medford 48
Bremen 44
Falkenstein 35
Atlanta 33
San Francisco 33
Des Moines 32
Boardman 30
Haiphong 30
Phoenix 30
Ann Arbor 26
Caserta 26
Council Bluffs 25
Orem 25
Wilmington 24
Brussels 22
Aversa 21
Rome 21
Rio de Janeiro 20
Brooklyn 19
Frankfurt am Main 19
Denver 18
Lappeenranta 18
Montreal 18
Hyderabad 17
Thái Nguyên 17
Biên Hòa 16
Helsinki 16
Mexico City 16
Munich 16
Boston 15
Houston 15
Nanjing 15
Vienna 15
Amsterdam 14
Belo Horizonte 14
Tokyo 14
Chicago 13
Milan 13
Toronto 13
Dhaka 12
Hải Dương 12
London 12
Memphis 12
Bến Tre 11
Chennai 11
Guangzhou 11
Nairobi 11
Nha Trang 11
Ninh Bình 11
Tashkent 11
Brasília 10
Campinas 10
Curitiba 10
Ercolano 10
Hangzhou 10
Napoli 10
Porto Alegre 10
Salvador 10
Shenzhen 10
Jinan 9
Johannesburg 9
Thái Bình 9
Turin 9
Columbus 8
Norwalk 8
Sivas 8
Stockholm 8
Baghdad 7
Bogotá 7
Cairo 7
Can Tho 7
Florence 7
Lấp Vò 7
Manchester 7
Totale 10.473
Salva come PNG Salva come JPEG
Nome #
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis 581
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 276
Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective 262
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A contemporary reappraisal 261
Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study 223
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience 185
MicroRNA-33 and SIRT1 influence the coronary thrombus burden in hyperglycemic STEMI patients 169
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 166
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease 165
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 163
Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience 160
Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions 159
Natural history of left ventricular hypertrophy in infants of diabetic mothers 157
Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy 156
Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapy 154
Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management 153
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 152
[Device therapy in chronic heart failure: a case of hypertrophic cardiomyopathy treated with cardiac contractility modulation therapy] 148
[The COMPASS study] 148
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: the emerging role of the Cardiomyopathy Team 143
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine 143
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 140
Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial 140
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry 136
Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives 134
ICARUS score for predicting peri-procedural bleeding in patients undergoing percutaneous coronary intervention with cangrelor 134
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 132
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 132
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 131
A call for action in bleeding prevention 131
Anti-inflammatory therapies for cardiovascular diseases: novel evidence, clinical implications, and future perspectives 130
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 129
[Evaluation and percutaneous treatment of severely calcified coronary lesions] 129
Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention 128
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 128
[Debate on antiplatelet monotherapy: P2Y12 inhibitor monotherapy in patients with coronary artery disease] 127
A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation 127
Role of LipoprotEin(a) in CardiovascuLar diseases and premature acute coronary syndromes (RELACS study): Impact of Lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease 126
Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go 124
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 124
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study 123
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options 121
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy 120
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 119
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry 118
[Gut microbiota and the cardiovascular system: current evidence and future perspectives] 118
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: Clinical outcomes at 1-year follow-up 117
Anticoagulation After Primary PCI: The Land of Promises and Uncertainty 116
Ticagrelor monotherapy after acute coronary syndrome: lessons from the ULTIMATE-DAPT trial 114
Antithrombotic Therapy after TAVI: Evidence, Discordance, and Clinical Implications 114
Mandatory reporting of coronary artery calcifications incidentally noted on chest multi-detector computed tomography: a multicentre experience 114
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up (vol 17, pg 512, 2018) 114
2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy? 112
Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement 111
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry 110
Early-onset MINOCA: Prognostic implications and considerations for practice 110
Are we ready for a gender-specific approach in interventional cardiology? 109
Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions 108
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice 108
A pragmatic approach for thrombotic prevention after acute coronary syndromes 107
Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis 107
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 107
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 106
Inflammation in patients undergoing transcatheter aortic valve implantation: a therapeutic target for the future? 105
Von Willebrand Factor and cardiovascular disease: from a biochemical marker to an attractive therapeutic target 105
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials 104
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study 104
Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology 102
Echocardiographic monitoring in cancer therapy: clinical guidance for cardiologists and oncologists 102
Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions 102
Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest 102
Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies 102
Severely calcified coronary artery lesions: focus on interventional management 101
Impact of SGLT2-inhibitors on acute kidney injury in diabetic patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) 101
Simulation Models of Therapy Intensification in Lipid-Lowering Medicine: Fact or Fantasy? 101
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 101
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 101
Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease 101
The year in cardiovascular pharmacotherapy 2022: landmark evidence at a glance 100
Impact of Clinical Presentation on Bleeding Risk after Percutaneous Coronary Intervention and Implications for the ARC-HBR Definition 100
Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention 99
Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy 99
Gender-related differences in changes of estimated bleeding risk in patients on dual antiplatelet therapy: the RE-SCORE multicenter prospective registry 98
A real-world multicenter study on left atrial appendage occlusion: The Italian multi-device experience 98
von Willebrand Factor and Venous Thromboembolism: Pathogenic Link and Therapeutic Implications 97
CYP2C19 Genotyping to Risk Stratify Patients After Coronary Stent Implantation: Time for a Personalized Approach? 97
OCEANIC-AF trial: factor XI inhibitors revolution in atrial fibrillation is on hold 96
AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain 96
Beyond the left ventricle: Why the right heart matters in Takotsubo syndrome 94
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions 94
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence 94
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial 94
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events 93
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" 93
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy 93
Perioperative care of cardiac patient’s candidate for non-cardiac surgery: a critical appraisal of emergent evidence and international guidelines 93
ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial 93
SGLT2 Inhibitors as the Backbone of Therapy for Cardiovascular and Renal Protection 92
Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy 92
Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients with ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial 92
Totale 12.840
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.055
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.055
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022768 0 1 8 28 194 11 12 121 21 93 59 220
2022/20231.332 129 73 32 93 121 72 4 69 672 8 26 33
2023/2024734 44 21 22 37 191 108 54 6 6 33 54 158
2024/20252.890 7 28 8 77 452 383 357 237 403 463 280 195
2025/202612.700 458 679 657 584 947 6.404 914 883 462 400 192 120
2026/20271.284 574 710 0 0 0 0 0 0 0 0 0 0
Totale 20.372